BioRestorative Therapies (BRTX) investor relations material

Executive summary

• Focused on developing cell-based therapies, with lead programs in spine/disc and metabolic disorders, and a growing biocosmeceutical product line.

• Phase 2 clinical trial for BRTX-100 in chronic lower back pain is ongoing; commercial sales of BioX cosmetic products began in Q1 2026.

• Accumulated deficit reached $172.1 million as of March 31, 2026; company expects continued losses as development progresses.

Financial highlights

• Q1 2026 revenue was $23,170, down from $25,000 in Q1 2025; product revenue of $11,870 from BioX, royalty revenue of $11,300.

• Net loss for Q1 2026 was $2,154,405, a significant improvement from $5,339,799 in Q1 2025.

• Operating expenses decreased 29.5% year-over-year, mainly due to lower stock-based compensation.

• Cash and cash equivalents increased to $3.1 million at March 31, 2026, from $1.5 million at year-end 2025.

• Working capital improved to $2.2 million from a deficit of $0.6 million at December 31, 2025.

Outlook and guidance

• Management anticipates continued net losses and negative cash flows as development and commercialization efforts continue.

• Current funds are insufficient for at least twelve months, raising substantial doubt about ability to continue as a going concern.

• Additional financing will be required to support operations and clinical development.